共 17 条
[1]
Hihg rate of post - therapeuticresistance after failure of macrolide - nitronidazole triple therapy tocure Helicobacter pylori infection:impact of two second -line therapiesin a randomized study. Peitz U,Sulliga M,Wolle K,et al. Alimentary Pharmacology and Therapeutics . 2002
[2]
Point mutations in the23S rRNA gene of Helicobacter pylori associated with different levelsof clarithromydn resistance. Versalovic J,Osato MS,Spakovsky K,et al. Journal of Antimicrobial Chemotherapy . 1997
[3]
Tight binding ofclarithromycin, its 14 - (R) - hydroxy metabolite, and erythromycin toHelicobacter pylori ribosomes. Goldman RC,Zakula D,Flamm R,et al. Antimicrobial Agents and Chemotherapy . 1994
[4]
Mutations in 23S rRNAare associated with clarithromycin resistance in Helicobacter pylori. Versalovic J,Shortridge D,Kibler K,et al. Antimicrobial Agents and Chemotherapy . 1996
[5]
Antibiotic resistance ofHelicobacter pylori strains in Japanese children. Kato S,Fujimura S,Udagawa H,et al. Journal of Clinical Microbiology . 2002
[6]
Clarithromycin asmonotherapy for eradication of Helicobacter pylori: a randomized,double-blind trial. Peterson WL,Graham DY,Marshall B,ct al. The American journal of Gastroenterology . 1993
[7]
Prevalence and rapid identificationof clarithromycin Helicobacter pylori isolates in children. Yang YJ,Yang JC,Jeng YM,et al. Pediatric Infectious Disease . 2001
[8]
Medical of treatment of peptic ulcer disease:practice guideline. Soll AH. The Journal of The American Medical Association . 1996
[9]
Cloning and sequence analysis oftwo copies of a 23S rRNA gene from Helicobacter pylori andassociation of clarithromydn resistance with 23S rRNA mutation. Taylor DE,Ge Z,Puryeh D,et al. Antimicrobial Agents and Chemotherapy . 1997
[10]
PCR-oligonudeotideligation assay to determine the prevalence of 23S rRNA gene mutationsin clarithromydn resistance Helicobacter pylori. Stone GG,Shortridge D,Veerealovic J,et al. Antimicrobial Agents and Chemotherapy . 1997